PlasFree - Revolutionizing Massive Bleeding Treatment

Over 192,000 patients die every year due to injury associated blood loss in the US [i]. Most of the treatment options are focussed on coagulation enhancement, however, these treatments of massive bleeding result in insufficient outcome and in some cases death.

In contrast, there are several treatments for hyperfibrinolysis that also contribute to massive bleeding. Hyperfibrinolysis occurs when fibrinolytic activity is potentially faster than fibrin formation such that clot integrity is threatened.

Plasfree ltd, has developed an innovative extracorporeal device that effectively and specifically extracts plasma proteins responsible for hyperfibrinolysis.

Using PlasFree medical device, physician can improve transfused plasma and shift the haemostasis from hyperfibrinolysis to coagulation and subsequently preventing massive bleeding.

Pre-clinical trials in a murine model demonstrated a significant reduction in blood loss in animals treated with our unique plasma filtration system compared to the control. The Company has demonstrated that administration of plasma free of fibrinolytic proteins result in <40% blood loss compared to the gold standard procedures ⁱⁱ. Moreover, the clinical evaluation of these animals demonstrated better physiological parameters, including: red blood cell number and plasma electrolytic content levels.

Plasfree is offering an innovative device, addressing an untapped market, improving transfused plasma and subsequently saving lives.

[i] The National Trauma Institute (NTI)

ⁱⁱTransfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients with Severe Trauma. The PROPPR Randomized Clinical Trial. JAMA February 3, 2015 Volume 313, Number 5.